Leap Therapeutics History
Our History
First patient dosed with TRX518 001
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
First patient dosed with TRX518 001
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Team
Luke Andersen
Finance
.jpg)
Jay Baum, Ph.D.
Translational Medicine
Amy Belliveau
Manufacturing
Adam Connelly
Manufacturing
Alex V. De Windt, MD
Pharmacovigilance
Marina Escudero
Clinical Development
Christine Granfield
Regulatory
Michael Haas, Ph.D.
Research
Peter Hocknell, Ph.D.
Manufacturing
Michael Kagey, Ph.D.
Research
Sri Kolluri
Clinical
Jennie Lee
Manufacturing
Gus Lawlor
Chief Operating Officer
Christine Mandell
Pharmacovigilance
Matthew Lederhos
Finance
Hank Piel
Quality
Diane Piper
Clinical
Kevin Lloyd
Program & Alliance Management
Jonathan Miller
Business Development
Chris Mirabelli, Ph.D.
Chairman of the Board
Walter Newman, Ph.D.
Senior Research Fellow
Mark O'Mahony
Chief Manufacturing Officer
Douglas Onsi
President & CEO
Lianna Sifferlen
Clinical
Cyndi Sirard, M.D.
Chief Medical Officer
Robert Steinberg
Operations
Mathis Thoma
Clinical
Steve Tokatlyan
Information Technology
2006
First US patent filed for TRX518
2009
First patient dosed with DKN-01 by Eli Lilly
2010
First patient dosed with TRX518 at Memorial Sloan Kettering Cancer Center
2010
First US patent granted covering sequence of DKN-01
2016
Leap Therapeutics launched
2017
Leap Therapeutics becomes publicly listed on NASDAQ: LPTX
2017
Initiated collaboration with Merck to evaluate DKN-01 in combination with Keytruda
2018
Initiated collaboration with Pfizer/Merck KGaA to evaluate TRX518 in combination with Bavencio
2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01
2020
Leap Therapeutics Announces Orphan Drug Designation of DKN-01 for the Treatment of Gastric/Gastroesophageal Junction Cancer and Closes $45 million Public Offering of Common Stock
Board of Directors
Chris Mirabelli, Ph.D.
Chairman of the Board, Leap Therapeutics
Chairman and CEO of Waypoint Holdings
Doug Onsi, J.D.
President & CEO, Leap Therapeutics
Co-Founder of NuBiyota
James Cavanaugh, Ph.D.
Managing Director at HealthCare Ventures
CEO and President of Angiogenesis Foundation
Joseph Loscalzo, M.D., Ph.D, M.A.
Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital
Monica M. Bertagnolli, MD, FASCO
Chief, Division of Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Professor of Surgery, Harvard Medical School, Boston
Scientific Advisory Board
David Tuveson, M.D., Ph.D.
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory
Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
Senior Vice President and Chief Clinical Strategy Officer; Chief, Division of Women's Cancers, Dana Farber Cancer Institute; Director, Breast Oncology Program, Susan F. Smith Center for Women's Cancers; Thompson Chair in Breast Cancer Research Institute Physician; Professor of Medicine, Harvard Medical School
Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
Professor of Medicine at Duke University Medical Center, Director of the Phase I Biomarker Laboratory and Associate Director of the Duke Center for Cancer Immunotherapy
President and Chief, Research and Development, at BioNTech US; Scientific Advisory Committee for Stand up to Cancer; Board of Directors of the Damon Runyon Cancer Research Foundation, Alkermes plc. and Infinity Therapeutics